Trying to break from the decade-old practice of using BTK inhibitors indefinitely to treat blood cancer, AstraZeneca has ...

Calquence plus Venclexta, with or without Gazyva, improved progression-free survival over the standard-of-care ...

Positive results from the AMPLIFY Phase III trial have shown that adding AstraZeneca’s Calquence (acalabrutinib) to ...

Data from the Phase I/II TRANSCEND CLL 004 study evaluating the combination of Bristol Myers Squibb’s (BMS’s) Breyanzi ...

Data from Eli Lilly and AstraZeneca could help doctors decide treatment order in chronic lymphocytic leukemia. Elsewhere, ...

Positive” results from the AMPLIFY Phase III trial showed AstraZeneca’s (AZN) Calquence in combination with venetoclax demonstrated a ...

Calquence (acalabrutinib) is a brand-name oral tablet that’s prescribed for certain types of cancer in adults. As with other drugs, Calquence can cause side effects, such as low levels of blood ...

Developments in chronic lymphocytic leukemia (CLL) this year included the first CAR T-cell therapy approval for the chronic ...

Calquence (acalabrutinib) is a prescription drug that’s used to treat certain types of leukemia and lymphoma, which are blood cancers. Calquence can cause side effects that range from mild to ...

SAN DIEGO -- A fixed-duration oral combination significantly reduced the risk of disease progression or death compared with ...

AstraZeneca’s fast-growing BTK inhibitor Calquence is already challenging class leader Imbruvica from Johnson & Johnson/AbbVie in the treatment of chronic lymphocytic leukaemia (CLL).

AstraZeneca has received another boost to its aspirations in oncology with the FDA approval of Calquence, a next generation treatment for mantle cell lymphoma (MCL). Calquence (acalabrutinib ...